4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
| Title | Journal |
|---|---|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Discovery of small molecule human FPR1 receptor antagonists. | Bioorganic & medicinal chemistry letters 20110515 |
| Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. | Nephrology (Carlton, Vic.) 20110201 |
| A predictive ligand-based Bayesian model for human drug-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. | Bioorganic & medicinal chemistry 20101101 |
| Adherence with urate-lowering therapies for the treatment of gout. | Arthritis research & therapy 20090101 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. | Annals of the rheumatic diseases 20080501 |
| MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. | Molecular cancer therapeutics 20080501 |
| 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies. | Bioorganic & medicinal chemistry letters 20080115 |
| HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. | Drug metabolism and disposition: the biological fate of chemicals 20080101 |
| Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity. | Journal of medicinal chemistry 20071227 |
| Molecular epidemiology of malaria in Cameroon. XXVI. Twelve-year in vitro and molecular surveillance of pyrimethamine resistance and experimental studies to modulate pyrimethamine resistance. | The American journal of tropical medicine and hygiene 20070801 |
| Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. | Drug metabolism and disposition: the biological fate of chemicals 20070601 |
| Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins. | European journal of pharmacology 20070410 |
| Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20070301 |
| Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. | Journal of biomolecular screening 20070301 |
| In silico prediction of pregnane X receptor activators by machine learning approaches. | Molecular pharmacology 20070101 |
| Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9. | Drug metabolism and disposition: the biological fate of chemicals 20061201 |
| Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. | Drug metabolism and disposition: the biological fate of chemicals 20061001 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Clinical trials of uric acid lowering for coronary heart disease risk reduction. | The American journal of medicine 20060401 |
| Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones. | Bioorganic & medicinal chemistry letters 20060215 |
| Macrophage uptake and recycling of ascorbic acid: response to activation by lipopolysaccharide. | Free radical biology & medicine 20051201 |
| Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Combined effects of GSTP1 and MRP1 in melanoma drug resistance. | British journal of cancer 20050725 |
| Chondrocyte transport and concentration of ascorbic acid is mediated by SVCT2. | Biochimica et biophysica acta 20050630 |
| High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. | Journal of biomolecular screening 20050601 |
| UDP-glucuronosyltransferases and clinical drug-drug interactions. | Pharmacology & therapeutics 20050401 |
| Ascorbate uptake in pig coronary artery endothelial cells. | Molecular and cellular biochemistry 20050301 |
| Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. | British journal of pharmacology 20041201 |
| Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. | Journal of the American Society of Nephrology : JASN 20041101 |
| Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. | European journal of clinical pharmacology 20040801 |
| Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. | Molecular pharmacology 20040401 |
| Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. | Drug metabolism and disposition: the biological fate of chemicals 20040301 |
| Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. | Bioorganic & medicinal chemistry letters 20040119 |
| Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. | The Journal of pharmacology and experimental therapeutics 20040101 |
| Differential effects of glucose on dehydroascorbic acid transport and intracellular ascorbate accumulation in astrocytes and skeletal myocytes. | Brain research 20031212 |
| Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport. | Toxicology and applied pharmacology 20031115 |
| Identification and prediction of promiscuous aggregating inhibitors among known drugs. | Journal of medicinal chemistry 20031009 |
| Functional expression of the multidrug resistance protein 1 in microglia. | The Journal of pharmacology and experimental therapeutics 20031001 |
| UV or X-irradiation increases the cytoplasmic accumulation of rhodamine 123 in various cancer cell lines. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20030801 |
| Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). | Molecular pharmacology 20030201 |
| Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | Archives of biochemistry and biophysics 20030101 |
| Accumulation of intracellular ascorbate from dehydroascorbic acid by astrocytes is decreased after oxidative stress and restored by propofol. | Glia 20020801 |
| CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20020701 |
| Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. | Cancer research 20020601 |
| Free radical scavenging properties of sulfinpyrazone. | Free radical research 20020601 |
| Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). | Pharmacology 20020101 |
| Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). | The Journal of biological chemistry 20011207 |
| Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. | The Journal of biological chemistry 20011012 |
| Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. | Cancer research 20010715 |
| Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. | Drug metabolism and disposition: the biological fate of chemicals 20010501 |
| A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. | Xenobiotica; the fate of foreign compounds in biological systems 19990301 |
| Acute renal failure due to sulfinpyrazone. | The American journal of the medical sciences 19980501 |
| Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. | European journal of drug metabolism and pharmacokinetics 19970101 |
| Antiplatelet therapy in the prevention of stroke. | Drugs 19910101 |
| Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. | The Journal of clinical investigation 19900201 |
| Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin. | American journal of kidney diseases : the official journal of the National Kidney Foundation 19860501 |
| Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. | European journal of clinical pharmacology 19860101 |
| [Acute tubulo-interstitial nephropathy associated with ingestion of sulfinpyrazone]. | Presse medicale (Paris, France : 1983) 19850223 |
| Sulfinpyrazone: risk for renal insufficiency. | Archives of internal medicine 19840301 |
| [Acute interstitial nephritis and kidney failure requiring dialysis after sulfinpyrazone therapy]. | Acta medica Austriaca 19840101 |
| Acute renal failure secondary to sulfinpyrazone treatment after myocardial infarction. | Nephron 19840101 |
| Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. | Thrombosis and haemostasis 19831230 |
| Sulfinpyrazone-associated acute renal failure. | Clinical nephrology 19830701 |
| Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction. | Clinical nephrology 19830301 |
| Oliguric acute renal failure after treatment with sulfinpyrazone. | Clinical nephrology 19830101 |
| [Sulfinpyrazone-associated renal failure (author's transl)]. | Deutsche medizinische Wochenschrift (1946) 19820709 |
| Non oliguric acute renal failure after treatment with sulfinpyrazone. | Clinical nephrology 19820501 |
| Acute renal failure following sulfinpyrazone therapy. | South Dakota journal of medicine 19820401 |
| Sulphinpyrazone--induced decrease in renal function: a review of reports with discussion of pathogenesis. | Acta clinica Belgica 19820101 |
| Renal dysfunction due to anturane. | The New England journal of medicine 19811105 |
| Acute renal dysfunction due to sulfinpyrazone therapy in post-myocardial infarction cardiomegaly: reversible hypersensitive interstitial nephritis. | American heart journal 19810801 |
| Renal dysfunction due to anturan. | The New England journal of medicine 19810709 |
| Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. | Japanese heart journal 19810701 |
| Sulfinpyrazone induced uric acid urolithiasis with acute renal failure. | Connecticut medicine 19810701 |
| Sulphinpyrazone-induced acute renal failure. | British medical journal (Clinical research ed.) 19810221 |
| [Acute renal failure induced by sulfinpyrazone (author's transl)]. | Nephrologie 19810101 |
| Are agents affecting platelet functions clinically useful? | The American journal of medicine 19761201 |
| Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy. | Archives of internal medicine 19760901 |
| Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout. | British medical journal 19760710 |